TY - JOUR
AU - Ciardiello, Fortunato
AB - Cetuximab and panitumumab have been approved for the treatment of metastatic colorectal cancer when used alone or in combination with irinotecan. Although EGFR is expressed in most metastatic colorectal tumors, only a subset of patients derive clinical benefit from treatment with EGFR inhibitors. The experimental and clinical evidence supporting the use ofKRAStesting for selecting patients for treatment with anti-EGFR monoclonal antibodies is discussed.
TI - Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
JF - Nature Reviews Clinical Oncology
DO - 10.1038/nrclinonc.2009.111
DA - 2009-07-28
UR - https://www.deepdyve.com/lp/springer-journals/implications-for-kras-status-and-egfr-targeted-therapies-in-metastatic-1l5BsJFCg9
SP - 519
EP - 527
VL - 6
IS - 9
DP - DeepDyve
ER -